Evidence map›Paper›PMID 35898405›Full record

ReviewVascular health and risk management2022

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance.

Xiaoming Jia, Mahmoud Al Rifai, Anum Saeed, Christie M Ballantyne, Salim S Virani

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Vascular health and risk management, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The landscape and trajectory of global CRISPR therapeutics.Molecular therapy. Nucleic acids · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoming JiaDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Mahmoud Al RifaiDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0002-6933-790X
Anum SaeedDepartment of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Christie M BallantyneDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Salim S ViraniDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.ORCID 0000-0001-9541-6954

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholesterol (LDL-C) and impact on cardiovascular outcomes. Since the approval of commercial use for PCSK9 inhibitors in 2015, we have also gained significant experience in the use of these therapeutics in the real-world setting. In this article, we review current guideline recommendations, clinical trial evidence on efficacy and safety as well as data on cost-effectiveness, prescription and adherence. We focus primarily on the monoclonal antibody class of PCSK9 inhibitors in this review while also touching on other types of therapeutics that are under development.

Indexed as

Anticholesteremic AgentsCardiovascular DiseasesHeart Disease Risk FactorsHumansPCSK9 InhibitorsProprotein Convertase 9Risk FactorsAnticholesteremic AgentsPCSK9 InhibitorsPCSK9 protein, humanProprotein Convertase 9CVD preventionlipidsPCSK9 inhibitor

Identifiers

PMID35898405
PMCPMC9309324

What OpenQuestion holds

Texttitle and abstract
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.